Acasti Pharma, Inc. (ACST)
NASDAQ:ACST

Acasti Pharma Stock Analysis & Ratings

Acasti Pharma Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Acasti Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

ACST

ACST Stock Stats

Previous Close$1.39
Open$1.38
Bid1.36 x 400
Ask1.4 x 100
Today’s Range$1.35 - $1.3847
52-Week Range$1.04 - $9.76
Volume206.01K
Average Volume1.31M
Market Cap$59.79M
Beta1.80
P/E Ratio-30.5
EPS-0.04
Earnings DateFeb 17, 2022

Company Description

Acasti Pharma, Inc.

Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
Sector
Healthcare
Industry
Biotechnology
CEO
Janelle D'Alvise
Employees
32
Website
www.acastipharma.com
ISIN
CA00430K8730
Address
3009 Boulevard de la Concorde East, Laval, QC, H7E 2B5, CA

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

ACST FAQ

What was Acasti Pharma’s price range in the past 12 months?
Acasti Pharma lowest stock price was $1.04 and its highest was $9.76 in the past 12 months.
    What is Acasti Pharma’s market cap?
    Acasti Pharma’s market cap is $59.79M.
      What is Acasti Pharma’s price target?
      The average price target for Acasti Pharma is $6.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $6.00. The average price target represents 344.44% Increase from the current price of $1.35.
        What do analysts say about Acasti Pharma?
        Acasti Pharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Acasti Pharma’s upcoming earnings report date?
          Acasti Pharma’s upcoming earnings report date is Feb 17, 2022 which is in 29 days.
            How were Acasti Pharma’s earnings last quarter?
            Acasti Pharma released its earnings results on Nov 10, 2021. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.03.
              Is Acasti Pharma overvalued?
              According to Wall Street analysts Acasti Pharma’s price is currently Undervalued.
                Does Acasti Pharma pay dividends?
                Acasti Pharma does not currently pay dividends.
                What is Acasti Pharma’s EPS estimate?
                Acasti Pharma’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Acasti Pharma have?
                Acasti Pharma has 26,050,000 shares outstanding.
                  What happened to Acasti Pharma’s price movement after its last earnings report?
                  Acasti Pharma reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.55%.
                    Which hedge fund is a major shareholder of Acasti Pharma?
                    Currently, no hedge funds are holding shares in ACST

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis